ArticleFrontiers in microbiology2026
Integrated gut microbiome and serum lipidomics reveals microbial-lipid interactions for predicting incident metabolic syndrome: a nested case-control study.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic syndrome (MetS) is a multifactorial disorder characterized by obesity, dyslipidemia, hypertension, and insulin resistance. Although gut microbiota and lipid metabolism are both known to influence MetS development, their interactions remain incompletely characterized. Methods: We conducted an exploratory nested case-control study within a prospective health examination cohort. We selected 100 participants (50 incident MetS cases and 50 matched controls) based on age, sex, and baseline MetS components. Gut microbial profiles were characterized by metagenomic sequencing, and serum lipid metabolites were measured using high-resolution mass spectrometry. Multi-omics integration was performed using correlation-based feature fusion. We constructed a support vector machine (SVM) model, optimized with recursive feature elimination (RFE) and five-fold cross-validation, to predict the incidence risk of MetS. Results: MetS participants differed from controls in gut microbial composition, metabolic pathway activities, and lipidomic profiles. Circos analysis revealed positive associations between Blautia and sphingomyelins and negative associations between Bacteroides and triglycerides. The integrated model combining microbiota and lipidomic features demonstrated strong discrimination in the training set (AUC = 0.995, 95% CI: 0.987-0.999) and acceptable performance in the validation set (AUC = 0.722, 95% CI: 0.525-0.919). Conclusion: Integration of baseline gut microbiota and lipidomic data revealed specific pre-disease microbial-lipid signatures, including positive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.